Havemeyer Place LP Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Havemeyer Place LP acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel.com reports. The firm acquired 3,510 shares of the company’s stock, valued at approximately $2,375,000.

A number of other institutional investors have also recently added to or reduced their stakes in IDXX. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of a number of recent analyst reports. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDXX opened at $562.16 on Friday. The firm has a market cap of $44.34 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company’s 50-day moving average price is $563.05 and its 200 day moving average price is $632.14. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.